INT268903

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.75
First Reported 2007
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 0.83
Pain Relevance 0.20

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

enzyme regulator activity (Sln)
Anatomy Link Frequency
blood 1
Sln (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Bioavailability 12 94.68 High High
Neuritis 1 84.08 Quite High
Pain 4 5.00 Very Low Very Low Very Low
imagery 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Renal Failure 1 87.44 High High
Optic Neuritis 1 84.56 Quite High
Blindness 1 82.56 Quite High
Nephrotoxicity 1 82.20 Quite High
Necrosis 1 79.92 Quite High
Encephalopathy 1 78.64 Quite High
Cardiovascular Disorder Under Development 1 77.12 Quite High
Toxicity 5 75.92 Quite High
Cancer 2 55.08 Quite High
Diabetes Mellitus 24 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This knowledge can be used to adjust degradation of SLN and consequently drug release in a controlled way (Olbrich and Muller 1999).
Protein_catabolism (degradation) of SLN
1) Confidence 0.75 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2676823 Disease Relevance 0.08 Pain Relevance 0.03
The longer the ethylene oxide chains are in the molecule, the more hindered is the anchoring of the lipase/co-lipase complex and consequently the degradation of the SLN.
Protein_catabolism (degradation) of SLN
2) Confidence 0.65 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2676823 Disease Relevance 0.07 Pain Relevance 0.03
SLN show different degradation rates by the lipolytic enzyme pancreatic lipase as a function of their composition (lipid matrix, stabilizing surfactant) and it has been demonstrated that the longer the fatty acid chains of the acylglycerols are, the slower is their degradation (Olbrich and Muller 1999).
Protein_catabolism (degradation) of SLN
3) Confidence 0.65 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2676823 Disease Relevance 0 Pain Relevance 0.05
The additional advantage of the SLN are the large scale production, protection of the drug against chemical degradation, ease of modulation of the drug release profile and high drug pay load3.
Protein_catabolism (degradation) of SLN
4) Confidence 0.59 Published 2008 Journal Indian Journal of Pharmaceutical Sciences Section Body Doc Link PMC2792476 Disease Relevance 0.68 Pain Relevance 0.08
Afterwards, it can be postulated that SLN undergo physiological degradation and the insulin enter into the blood circulation.
Protein_catabolism (degradation) of SLN in blood
5) Confidence 0.58 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2676823 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox